MD2552G2 - Medicament in the form of suppository - Google Patents

Medicament in the form of suppository

Info

Publication number
MD2552G2
MD2552G2 MDA20040128A MD20040128A MD2552G2 MD 2552 G2 MD2552 G2 MD 2552G2 MD A20040128 A MDA20040128 A MD A20040128A MD 20040128 A MD20040128 A MD 20040128A MD 2552 G2 MD2552 G2 MD 2552G2
Authority
MD
Moldova
Prior art keywords
suppository
medicament
propolis
rectum
vitamin
Prior art date
Application number
MDA20040128A
Other languages
Romanian (ro)
Russian (ru)
Other versions
MD2552F1 (en
Inventor
Людмила РАЗБОРСКИ
Ион ШАПОВАЛ
Original Assignee
Людмила РАЗБОРСКИ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Людмила РАЗБОРСКИ filed Critical Людмила РАЗБОРСКИ
Priority to MDA20040128A priority Critical patent/MD2552G2/en
Publication of MD2552F1 publication Critical patent/MD2552F1/en
Publication of MD2552G2 publication Critical patent/MD2552G2/en

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

The invention refers to the pharmaceutical industry, in particular to the suppositories used for treatment of inflammatory processes in the rectum and urogenital system.Summary of the invention consists in that the medicament in the form of suppository contains phenolic compounds of propolis, oleic solution of vitamin E, glycerol, semisynthetic glycerides in the following component ratio, calculated for a suppository with the weight of 2,00 g:
MDA20040128A 2004-05-19 2004-05-19 Medicament in the form of suppository MD2552G2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MDA20040128A MD2552G2 (en) 2004-05-19 2004-05-19 Medicament in the form of suppository

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MDA20040128A MD2552G2 (en) 2004-05-19 2004-05-19 Medicament in the form of suppository

Publications (2)

Publication Number Publication Date
MD2552F1 MD2552F1 (en) 2004-09-30
MD2552G2 true MD2552G2 (en) 2005-06-30

Family

ID=33095718

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20040128A MD2552G2 (en) 2004-05-19 2004-05-19 Medicament in the form of suppository

Country Status (1)

Country Link
MD (1) MD2552G2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2498810C1 (en) * 2012-05-10 2013-11-20 Государственное автономное учреждение Республики Башкортостан "Центр аграрных исследований" Antioxidant preparation with 5-aminosalicylic acid, quercetin and propolis extract

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2225213C2 (en) * 2002-03-04 2004-03-10 Пятигорская государственная фармацевтическая академия Suppository "apiprost" eliciting wound-healing effect

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2225213C2 (en) * 2002-03-04 2004-03-10 Пятигорская государственная фармацевтическая академия Suppository "apiprost" eliciting wound-healing effect

Also Published As

Publication number Publication date
MD2552F1 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
BRPI0717845A2 (en) Use of compounds, pharmaceutical compositions and methods for the treatment and / or prophylaxis of diseases that can be treated with HDL-cholesterol elevating agents and compounds.
EP2377528A3 (en) Fatty acid metabolism inhibitors for use in the treatment of cancer
MXPA06014510A (en) Compositions and methods for treating inflammatory disorders.
IL158559A0 (en) Acne treatment
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
SG170826A1 (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor
GB9807639D0 (en) Anti-inflammatory agents
NZ597489A (en) Methods for treating conditions associated with MASP-2 dependent complement activation
AR054255A1 (en) TREATMENT OF INTESTINAL DYSFUNCTION IN HIV PATIENTS
NZ587088A (en) Treatment of metastatic stage prostate cancer with degarelix
MY172372A (en) Compositions and methods for lowering triglycerides
WO2011113013A3 (en) Methods and compositions for treating viral or virally-induced conditions
CL2008001626A1 (en) Compounds derived from fused heterocycles, a pharmaceutical agent that comprises them and their use in the prophylaxis and treatment of cancer.
PT2040755E (en) Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity
DE602008005316D1 (en) TABLETTED ATAZANA-CONTAINING COMPOSITIONS
NZ577393A (en) Use of 3-alpha-androstanediol, optionally in combination with a pde5 inhibitor, in the treatment of sexual dysfunction
CL2008003057A1 (en) Pharmaceutical combination comprising a purine derivative and a corticosteroid, beta-2 adrenoceptor agonist, antimuscarinic agent, among others; pharmaceutical composition; and its use to treat inflammatory or obstructive airway diseases.
MXPA02002681A (en) Use of g(a)-linolenic acid metabolites in the manufacture of a medicament for the treatment or prevention of cancer.
DE602008005896D1 (en) TABLETTED ATAZANA-CONTAINING COMPOSITIONS
MY172984A (en) Use of lactobacillus rhamnosus gg in combination with a long chain polyunsaturated fatty acid for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant
PH12020551573A1 (en) Pharmaceutical compositions for inhibiting inflammatory cytokines
PT1838716E (en) Olanzapine pamoate dihydrate
EA200700353A1 (en) ANTIMICROBANO ACTION MEANS
MD2552G2 (en) Medicament in the form of suppository
AR074190A1 (en) ACIDOSIS CONTROLLING AGENT FOR A RUMINANT. COMPOSITION. METHOD. I THINK. USE.

Legal Events

Date Code Title Description
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees